50th week of 2012 patent applcation highlights part 36 |
Patent application number | Title | Published |
20120315255 | Hepatocyte Based Insulin Gene Therapy For Diabetes - A method and vectors for controlling blood glucose levels in a mammal are disclosed. In one embodiment, the method comprises the steps of: treating the hepatocyte cells of a patient with a first, second or third vector, wherein the first vector comprises a promoter enhancer, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase and an albumin 3′UTR and lacks an HGH intron, wherein the second vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site and an albumin 3′UTR and lacks a promoter enhancer, wherein the third vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site, an albumin 3′UTR and a promoter enhancer and observing the patient's insulin levels, wherein the patient's insulin levels are controlled. | 2012-12-13 |
20120315256 | USE OF TRANSFORMING GROWTH FACTOR - BETA 1 (TGF-B1) INHIBITOR PEPTIDES FOR THE TREATMENT OF CORNEAL FIBROSIS AND/OR HAZE - The invention refers to the use of transforming growth factor-beta 1 (TGF-β1) inhibitor peptides or polynucleotides encoding said peptides for the prevention and/or treatment of corneal fibrosis and/or corneal haze. | 2012-12-13 |
20120315257 | METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS - Cells present in adipose tissue are used to treat patients, including patients with PVD and related diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit. | 2012-12-13 |
20120315258 | BACILLUS STRAINS AND METHODS FOR REDUCING E. COLI DISEASE AND ENHANCING PERFORMANCE - strains that inhibit pathogenic swine | 2012-12-13 |
20120315259 | METHOD AND COMPOSITION FOR SKIN CARE COMPRISING CORD BLOOD SERUM OR PLASMA OR COMPONENTS THEREOF - A method and composition for treating dermatological conditions and improving skin condition and helping hair to grow or thicken involves removing extracts including beneficial secretions from mesenchymal stem cells or other cells with regenerative properties to use itself or components thereof alone or with other skin or hair care reagents as a topical ointment or formula to apply to the skin or hair topically for therapeutic and cosmetic purposes. | 2012-12-13 |
20120315260 | Compositions and Methods to Prevent and Treat Biofilms - Compositions and methods to treat biofilms are disclosed based on the discovery of the role of the disaccharide trehalose in microbial biofilm development. In various embodiments to treat body-borne biofilms systemically and locally, the method includes administering trehalase, the enzyme which degrades trehalose, in combination with other saccharidases for an exposition time sufficient to adequately degrade the biofilm gel matrix at the site of the biofilm. The method also includes administering a combination of other enzymes such as proteolytic, fibrinolytic, and lipolytic enzymes to break down proteins and lipids present in the biofilm, and administering antimicrobials for the specific type(s) of infectious pathogen(s) underlying the biofilm. Additionally, methods are disclosed to address degradation of biofilms on medical device surfaces and biofilms present in industrial settings. | 2012-12-13 |
20120315261 | ANTIBACTERIAL AUXILIARY AGENT COMPRISING KOMBU EXTRACT AS ACTIVE INGREDIENT, ANTIBACTERIAL COMPOSITION, AND FOOD OR BEVERAGE - Disclosed are: a method for utilizing a kombu (kelp) extract as an antibacterial auxiliary agent; and a method for utilizing a combination of the antibacterial auxiliary agent, lactoperoxidase, glucose oxidase and glucose as an antibacterial composition having a potent antibacterial activity. Specifically disclosed are: an antibacterial auxiliary agent comprising a fraction having a molecular weight of 5000 or less and produced from a kombu extract as an active ingredient; an antibacterial composition comprising the antibacterial auxiliary agent, lactoperoxidase, glucose oxidase and glucose; an antibacterial composition as mentioned above, which additionally comprises xanthane gum; and a food or beverage containing the antibacterial composition. | 2012-12-13 |
20120315262 | STABILIZED OPEN FORM TRANSGLUTAMINASE AS A DIAGNOSTIC INDICTOR FOR AUTOIMMUNE DISEASES - The present invention relates to the diagnosis of disorders or dysfunctions characterized by autoimmune responses to the enzyme class of transglutaminases. The present invention provides a novel open structure of the transglutaminases in a stabilized form which renders new epitopes accessible for antibody-binding. | 2012-12-13 |
20120315263 | Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases - The invention provides a method and compositions for treating a subject with a lysosomal storage disease such as gaucher disease, by administering to a subject with a lysosomal storage disease a therapeutically effective amount of composition comprising at least one of a protease or peptidase in an amount sufficient to ameliorate, reduce or improve at least one symptom of the disease. The invention also provides dietary supplements for subjects having lysosomal storage diseases. | 2012-12-13 |
20120315264 | ZWITTERIONIC IMMUNOMODULATORS FOR THE TEATMENT OF ASTHMA AND ALLERGY - Methods and products for treating and protecting against asthma and allergic conditions are provided. The methods and products are related to certain naturally occurring and synthetic zwitterionic polymers which are found to induce certain T regulatory (Treg) cells and to exert immunosuppressive effects in vitro and in vivo. | 2012-12-13 |
20120315265 | HYDROGEL-FORMING POLYMER, AND PREPARATION PROCESS AND USES THEREOF - Disclosed herein are a hydrogel-forming polymer and a process of making the same. Also disclosed are a sustained-release pharmaceutical composition that contains a therapeutic agent and the aforesaid hydrogel-forming polymer, and a method for treating or preventing an ophthalmic disorder, which includes intraocularly administering into an eye of a mammal in need of such treatment a sustained-release pharmaceutical composition that contains an ophthalmic drug and the aforesaid hydrogel-forming polymer. | 2012-12-13 |
20120315266 | DETECTING COMPLEMENT ACTIVATION - Methods of detecting complement activation including steps of detecting in a sample from a subject a level of iC3b wherein the detecting involves specific interaction between the iC3b and a non-cross-reactive antibody thereto, comparing the detected level with a reference level, which reference level is within a range of about 10 ng/ml to about 5,000 ng/ml, wherein determination that the detected level is above the reference level indicates that the subject is suffering from or susceptible to undesirable and/or pathologic complement activation, and administering treatment to treat undesired complement activation if the detected level is above the reference level. Other methods of detecting complement activation with or without measuring iC3b are also provided. | 2012-12-13 |
20120315267 | NOVEL USES - The present invention relates to antibodies which multiple antigen specificities and their use in treating human diseases | 2012-12-13 |
20120315268 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Lyl antibody and bendamustine. | 2012-12-13 |
20120315269 | IMMUNOGLOBULIN-LIKE TRANSCRIPT (ILT) RECEPTORS AS CD8 ANTAGONISTS - Compositions and methods for inhibiting effector CD8 | 2012-12-13 |
20120315270 | RSV IMMUNOGENS, ANTIBODIES AND COMPOSITIONS THEREOF - The present invention provides immunogens that protect against RSV infection. The present invention also provides antibody proteins that protect against RSV infection. Such immunogens and antibody proteins are produced based on three-dimensional models also included in the invention. One model is of a complex between motavizumab and its antibody-binding domain on RSV fusion (F) protein. A second model is of a complex between 10 IF antibody and its antibody-binding domain on RSV F protein. The immunogens disclosed herein have been modified to elicit a humoral response against RSV F protein without eliciting a significant cell-mediated response against RSV. Such immunogens can comprise a scaffold into which RSV contact residues are embedded. The present invention also includes methods that utilize the disclosed three-dimensional models to produce immunogens and antibody proteins of the present invention. Also disclosed are methods of using the disclosed immunogens, for example to protect individuals from RSV infection. Also disclosed are methods of using the disclosed antibody proteins, for example to protect individuals from RSV infection. | 2012-12-13 |
20120315271 | METHODS FOR TREATING BONE CANCER BY ADMINISTERING A NERVE GROWTH FACTOR ANTAGONIST ANTIBODY - The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth factor (NGF). The NGF antagonist may be an anti-NGF (such as anti-hNGF) antibody that is capable of binding hNGF. | 2012-12-13 |
20120315272 | METHODS FOR PREVENTION AND TREATMENT OF INFLAMMATION USING ANTI-CHEMOKINE ANTIBODIES - It is possible to inhibit inflammatory processes by administration of antibodies to chemokines. Identification of chemokines which are over-produced makes it possible to block specific chemokine activity using antibodies to the over-expressed chemokines. | 2012-12-13 |
20120315273 | TREATING SKIN CANCER - This document provides methods and materials related to treating skin cancer. For example, methods and materials relating to the use of a taxane compound, an alkylating agent, and an anti-VEGF polypeptide antibody to treat skin cancer are provided. | 2012-12-13 |
20120315274 | Methods of Treating Glucose Metabolism Disorders - Methods of treating individuals with a glucose metabolism disorder such as diabetes, hyperglycemia, hyperinsulinemia or obesity by administering human FAM3D (family with sequence similarity 3, member D) are provided. Specifically a method of treating hyperglycemia resulting in a reduction of plasma glucose is provided. Additionally, a method of treating hyperinsulinemia resulting in a reduction of plasma glucose is provided. In addition, a method of treating glucose intolerance resulting in an increased glucose tolerance is provided. Pharmaceutical compositions are provided. | 2012-12-13 |
20120315275 | HUMANIZED ANTI-C5AR ANTIBODIES - The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor. | 2012-12-13 |
20120315276 | NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE - The present invention is directed to the neutralizing prolactin receptor antibody 002-H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling. | 2012-12-13 |
20120315277 | Compositions and Methods for the Therapy and Diagnosis of Influenza - The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection. | 2012-12-13 |
20120315278 | HUMAN BINDING MOLECULES HAVING KILLING ACTIVITY AGAINST ENTEROCOCCI AND USES THEREOF - Described are human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The molecules can be used in the diagnosis, prophylaxis, and/or treatment of a condition resulting from | 2012-12-13 |
20120315279 | COMPOSITIONS AND METHOD OF MODULATING GROWTH FACTOR FUNCTION - A method of modulating growth factor responses of cells expressing C3a receptor (C3aR) and C5a receptor (C5aR) and at least one growth factor receptor includes administering to the cells at least one agent that modulates C3aR and/or C5aR signaling of the cells. | 2012-12-13 |
20120315280 | ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TRACT - In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described with enhanced permeability to a compromised digestive tract. | 2012-12-13 |
20120315281 | TREATMENT OF RENAL INJURY - Methods for the treatment of renal injury include the use of arginase inhibitors in the treatment and prevention of diabetic nephropathy, albuminuria and azotemia amongst others, and methods for identifying agents for the treatment of renal injury. | 2012-12-13 |
20120315282 | Antibodies Specific for TGF-Beta - The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGFβ), including TGFβ1, TGFβ2 and TGFβ3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGFβ expression. | 2012-12-13 |
20120315283 | METHODS OF PROMOTING TISSUE GROWTH AND TISSUE REGENERATION - Described herein are methods of using soluble epoxide hydrolase inhibitors to modulate the levels of epoxyeicosatrienoic acids (EETs) in order to increase angiogenesis and promote wound healing and tissue regeneration. | 2012-12-13 |
20120315284 | COMPOSITION FOR ENHANCING TRAIL SENSITIVITY COMPRISING INHIBITORS FOR EXPRESSION OR ACTIVITY OF TIP41 AS A TARGET GENE OF TRAIL SENSITIZER - The present invention relates to a pharmaceutical composition, including inhibitors for expression or activity of TIP41 protein, for prevention and treatment of cancer. When the liver cancer cell lines, showing resistance to TRAIL, are treated with TIP41 siRNA and TRAIL, apoptosis is induced in cancer cell. The same effect is found in cases of lung cancer and colon cancer with resistance against TRAIL. Moreover, this induction of apoptosis by TIP41 siRNA and TRAIL was confirmed in tumor xenograft, which was injected with Huh7 liver cancer cells and then was subjected to TIP41 siRNA transfection and TRAIL treatment. In addition, it was confirmed through animal experiments in which the tumor size has reduced and apoptosis was induced by treatment with TIP41 siRNA and TRAIL. Of note, MKK7/JNK pathway was confirmed to mediate the apoptosis induced by the application of TIP41 siRNA and TRAIL. The apoptosis were verified to be caused by the activation of MKK7/JNK signaling pathway. Taken together, the present invention provide the strong evidence that the pharmaceutical composition, including inhibitors for TIP41 expression or activity can be used for cancer prevention and treatment as well as an anti-cancer adjuvant. Taken together, the pharmaceutical composition comprising inhibitors for expression or activity of TIP41 protein may be used for prevention and treatment of cancer or as an anti-cancer adjuvant. | 2012-12-13 |
20120315285 | Antibody Formulation - The present invention relates to novel pharmaceutical formulations, in particular novel pharmaceutical formulations in which the active ingredient comprises human antibodies to human interleukin I beta (IL-1β), in particular ACZ885 antibody, pharmaceutical formulations which are stable and aggregate-free upon storage and delivery. | 2012-12-13 |
20120315286 | COMPOSITIONS AND METHODS RELATED TO TIM 3, A TH1-SPECIFIC CELL SURFACE MOLECULE - The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease. | 2012-12-13 |
20120315287 | MIC-BINDING ANTIBODIES AND METHODS OF USE THEREOF - The technology described herein relates to antibodies and/or polypeptides which bind to MIC and inhibit MIC shedding. Methods of using such antibodies and/or polypeptides for the treatment of cancer are also described herein. | 2012-12-13 |
20120315288 | LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY - The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided. | 2012-12-13 |
20120315289 | Non-polysaccharide constituent of genus Dendrobium, usage for the non-polysaccharide constituent of genus Dendrobium and extracting method thereof - The present invention discloses a non-polysaccharide constituent for positively regulating the immune system in the therapy of allergic diseases. The non-polysaccharide constituent is extracted from genus Dendrobium by incubating in alcohol and extracting using solvents with different polarity. | 2012-12-13 |
20120315290 | INHIBITORS OF LL-37 MEDIATED IMMUNE REACTIVITY TO SELF NUCLEIC ACIDS - Methods and compositions for treating disease are provided. More particularly, methods and compositions of inhibiting pathogenic interferon production are prevented, which may be useful in the treatment of various diseases. In other embodiments, therapeutic compounds and methods for the treatment of autoimmune diseases and chronic inflammatory diseases and/or cancer are provided. One such method is a method for inhibiting pathogenic interferon production or inhibiting activation of plasmacytoid dendritic cells or treating an autoimmune or chronic inflammatory disease, which comprises inhibiting one or more of LL-37 and hCAP18. | 2012-12-13 |
20120315291 | PURINE DERIVATIVES AND THEIR PHARMACEUTICAL USES - The present invention relates to compounds of formula (I): | 2012-12-13 |
20120315292 | IMMUNOGENIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES - The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057. | 2012-12-13 |
20120315293 | Antigen Delivery Vectors and Constructs - The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals. | 2012-12-13 |
20120315294 | Needle-free administration of PRRSV vaccines - The invention provides novel methods and compositions for the vaccination of porcine animals against porcine reproductive and respiratory syndrome virus (PRRSV). Described herein are immunological and/or vaccine compositions comprising a DNA vector encoding a PRRSV protein, particularly a truncated ORF7 protein, which are administered to porcines using needle-free delivery. The plasmid can include more than one nucleic acid molecule such that the plasmid can express more than one antigen. Also disclosed are methods for using and kits employing such compositions. | 2012-12-13 |
20120315295 | Development of a Marker Foot and Mouth Disease Virus Vaccine Candidate That is Attenuated in the Natural Host - We have generated novel molecularly marked FMDV A | 2012-12-13 |
20120315296 | LENTIVIRAL GENE TRANSFER VECTORS AND THEIR MEDICINAL APPLICATIONS - The present invention relates to the design of gene transfer vectors and especially provides lentiviral gene transfer vectors suitable for either a unique administration or for iterative administration in a host, and to their medicinal application (such as vaccination against Immunodeficiency Virus, especially suitable in human hosts). Gene transfer vectors can be either integrative or non-integrative vectors. The invention encompasses prophylactic, therapeutic, symptomatic, and curative treatments of animals, including humans, as well as gene therapy and vaccination in vivo. | 2012-12-13 |
20120315297 | Treatment of Psychological Trauma - The present specification discloses methods of treating a psychological trauma in an individual using botulinum toxins and/or a Targeted Exocytosis Modulator, and compositions thereof. | 2012-12-13 |
20120315298 | LOCAL TREATMENT OF NEUROFIBROMAS - A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed. | 2012-12-13 |
20120315299 | PHARMACEUTICAL COMPOSITION FOR INTRACELLULAR ACIDIFICATION WITH CIS-UROCANIC ACID - A pharmaceutically acceptable agent able to acidify the cell cytoplasm, for the manufacture of a pharmaceutical composition useful for causing immunosuppression in a person or animal, where an effective amount of the agent is administered in an essentially non-dissociated form to the person or animal, and where the agent is admixed with a carrier to adjust the pH of the composition to the pH range 6.1 to 7.0. A pharmaceutical composition is also disclosed. | 2012-12-13 |
20120315300 | INSERTABLE MEDICAL DEVICES WITH A POROUS BED FOR DELIVERING NANO-CARRIERS TO A TARGET SITE AND METHODS OF PREPARING THE SAME - The invention discloses a method of coating a medical device. The method includes applying a coating composition on the medical device to form a layer on the medical device. The coating composition includes one or more of one or more biological agents and heparin dissolved in a mixture of a first solvent and a second solvent. The first solvent and the second solvent have different evaporation temperatures. Subsequently, at least a part of one of the first solvent and the second solvent present in the coating composition is evaporated to create a plurality of pores in the layer. Thereafter, one or more drugs are deposited in the plurality of pores. When the medical device is positioned and expanded at a target site, the one or more drugs are released from the plurality of pores. | 2012-12-13 |
20120315301 | Preparation of vesicle-type carbon nanotubes - A method to prepare new morphologies, especially vesicle-type, of carbon nanotubes (CNT) by supramolecular interactions between them and dendritic or linear-dendritic polymers and copolymers. Due to their water solubility, high functionality and unique properties, the prepared hybrid nanomaterials have excellent applicability in different fields especially in nanomedicine in comparison with usual CNTs. | 2012-12-13 |
20120315302 | LOW HYGROSCOPIC ARIPIPRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF - The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous Aripiprazole crystals is stored for an extended period. | 2012-12-13 |
20120315303 | METHODS AND INTRAVASCULAR TREATMENT DEVICES USING PACLITAXEL FOR TREATMENT OF ATHEROSCLEROSIS - Methods and intravascular treatment devices for treating atherosclerosis are provided. | 2012-12-13 |
20120315304 | SENSITIZATION OF IMMUNE SYSTEM AGAINST HAPTENIZED MELANOMA ANTIGENS - The metabolization of certain phenols, monophenols or benzenediols into reactive quinone compounds, in particular ortho-quinones and related reactive intermediates, which is brought about by oxidation of monophenols and benzenediols by proteins exhibiting tyrosinase activity, such as human tyrosinase and the related proteins TRP1 and TRP2. The compounds function as haptens that become covalently bound to the tyrosinase enzymes, in particular to histidine moieties, in or near the catalytic site of proteins exhibiting tyrosinase activity, such as tyrosinase, TRP1 and TRP2. An immune response is then to be mounted against these haptenized auto-antigens to treat malignancies. | 2012-12-13 |
20120315305 | Dry Powder Fibrin Sealant - The present invention relates to a dry powder fibrin sealant which comprises a mixture of fibrinogen and thrombin for use in surgery, trauma and other wounds or injuries. It further relates to novel formulations comprising said dry powder fibrin sealant for use in the treatment of wounds or for surgical intervention or as a topical hemostat. | 2012-12-13 |
20120315306 | PHARMACEUTICAL COMPOSITION AND PREPARATION FOR ORAL ADMINISTRATION - A pharmaceutical composition including drug-containing nanoparticles having an average particle diameter of from 10 nm to 150 nm, the pharmaceutical composition being obtained by mixing water with a poorly water soluble drug-containing, water miscible solution that contains a poorly water soluble drug having a water solubility of 50 μg/mL or less, a water soluble copolymer having a repeating unit represented by the following Formula (1), and a water miscible miscible solvent, wherein in Formula (1), n:m is within a range of from 0.25:0.75 to 0.95:0.05, R represents an alkyl group which may have a substituent, R | 2012-12-13 |
20120315307 | CELL CULTIVATION IN CHITOSAN ALGINATE HYDROGEL BEADS - The present invention relates to a method of producing a hydrogel matrix comprising cartilage-forming cells wherein alginate, chitosan and cartilage-forming cells are mixed and subsequently polymerised into beads. | 2012-12-13 |
20120315308 | METHODS AND DEVICES FOR CONTROLLING PARTICLE SIZE AND PARTICLE SIZE DISTRIBUTION - Methods and apparatus for continuously preparing a particulate material are provided. One method of the invention includes mixing a first solution comprising a solute dissolved in a solvent, with a second solution, thereby providing a first solution-second solution mixture; and introducing the mixture into the high-energy zone of a high shear dispersion system and dispersing the first solution-second solution mixture prior to significant particulate growth, whereby the dispersed mixture forms a suspension of particles of the solute; and wherein significant particulate growth has occurred when the average equivalent spherical diameter of at least one particle in the solution is greater than 10 micrometer. Integrated apparatuses for performing methods of the invention are also provided. | 2012-12-13 |
20120315309 | MODIFIED PECTINS, COMPOSITIONS AND METHODS RELATED THERETO - The present invention provides compositions of modified pectin and methods for preparing and using them. | 2012-12-13 |
20120315310 | BONE TISSUE IMPLANT COMPRISING LITHIUM IONS - The present invention is based on that local administration of lithium ions in bone tissue has been found to improve the bone formation and bone mass upon implantation of a bone tissue implant in said bone tissue. In particular, the invention relates to a bone tissue implant having an implant surface covered by an oxide layer comprising lithium ions and a method for the manufacture thereof. A blasting powder comprising lithium ions, a method for locally increasing bone formation, and the use of lithium ions or a salt thereof for manufacturing a pharmaceutical composition for locally increasing bone formation are also provided by the present invention. | 2012-12-13 |
20120315311 | ANTIVIRAL COMPOSITION AND METHOD OF USE - Disclosed herein is a method of reducing the risk of a rhinovirus infection, the method includes administering to a subject a composition comprising iota-carrageenan in an antiviral effective amount as an active antiviral ingredient. | 2012-12-13 |
20120315312 | CORE-SHELL PARTICLES WITH A HIGH CONTENT OF GLYCEROL, THEIR PRODUCTION AND USE - The invention relates to core-shell particles, the shell of which includes aggregated, hydrophobicized silicon dioxide particles, and the core of which includes a liquid phase, and in which the ratio of aggregated, hydrobicized silicon dioxide particles to the liquid phase, based on the total weight of the particles, is 2:98 to 40:60, where 60-100% by weight of glycerol is present in the liquid phase. The invention further encompasses the production of these core-shell particles and also their use for cosmetic purposes. | 2012-12-13 |
20120315313 | LIQUID-FILLED CHITOSAN-ANIONIC LIPOSOLUBLE SURFACTANT CAPSULE DISPERSIONS - The present invention generally relates to the field of membranes. In particular, the present invention relates to a composition comprising bodies surrounded by a membrane. The composition are for example edible compositions. One embodiment of the present invention relates to a composition containing an oily fraction, a hydrophilic fraction, and at least one body, wherein the body comprises a shell comprising several molecular layers of chitosan and at least one lipidic phosphatidic acid surfactant; and a content comprising an internal phase containing a hydrophilic component and/or a hydrophobic component. The Composition may be used to protect a food product or to deliver specific properties to a product, for example. | 2012-12-13 |
20120315314 | BASE MAKEUP COSMETIC AND METHOD FOR PRODUCING THE SAME - A base makeup cosmetic satisfying the relationship expressed by the following Formula (1) and the relationship expressed by the following Formula (2) and exhibiting a hue angle of the cosmetic in a range of from 40° to 80°, wherein, when incident light falls on a light-receiving surface from a direction at −45° relative to the light-receiving surface, the light-receiving surface being a surface of a coating layer obtained by applying the base makeup cosmetic, (C*45) and (angle h*45) respectively represent the chroma (C*45) and hue angle (angle h*45) of reflected light in a specular reflection direction (a direction at)45°; and, when incident light falls on the light-receiving surface from a direction at −45° relative to the light-receiving surface, (C*0) and (angle h*0) respectively represent the chroma (C*0) and hue angle (angle h*0) of reflected light in a diffuse reflection direction (a direction at 0°). | 2012-12-13 |
20120315315 | Foam Formulations Containing at Least One Triterpenoid - The invention relates to a foam formulation comprising an emulsion, comprising an oil phase and an aqueous phase, wherein the emulsion comprises at least one triterpenoid. Further the invention relates to anemulsion comprising an oil phase and an aqueous phase, wherein the emulsion comprises at least one triterpenoid selected from the group consisting of betulin, betulinic acid, lupeol, erythrodiol, oleanolic acid, (C | 2012-12-13 |
20120315316 | Reinforced Absorbable Synthetic Matrix For Hemostatic Applications - The present invention is directed to a reinforced absorbable hemostat comprising at least one hemostatic agent in a single layer of nonwoven synthetic fabric having a mixture of compressed fiber staples of a polyglycolide/polylactide copolymer and a polydioxanone. | 2012-12-13 |
20120315317 | Insect Repellent Devices - An insect repellent device that is wearable by a host or attachable to an object, such device comprised of: an elongated band having length and width comprised of an outer surface to face toward a host or object, an inner surface to face away from a host or object, a first end, a second end and at least one impervious region; at least one front panel having a plurality of apertures positioned over the second side opposite an impervious region and that is attached to the elongated band so as to form a vented pocket with an opening; an absorbent pad impregnated with natural oils that is slidably and removably insertable into the vented pocket; and, at least one means for securing connected to an end that provides the user with the ability to replace its absorbent impregnated pads instead of having to buy another new band. | 2012-12-13 |
20120315318 | TRANSDERMAL PREPARATION - A transdermal preparation comprising a multivalent metal chloride, a basic drug having an amino group, and an ester group-containing base material, is useful because of its excellent drug content stability. | 2012-12-13 |
20120315319 | GUIDED BONE REGENERATION MEMBRANE AND MANUFACTURING METHOD THEREOF - A guided bone regeneration material is disclosed. The guided bone regeneration material includes biodegradable fibers produced by an electro spinning method. The biodegradable fibers produced by the method include a silicon-releasing calcium carbonate and a biodegradable polymer. The silicon-releasing calcium carbonate is a composite of siloxane and calcium carbonate of vaterite phase. The biodegradable fibers may be coated with apatite. When the guided bone regeneration material is immersed in a neutral aqueous solution, silicon species ions are eluted from the calcium carbonate. The guided bone regeneration material excels in bone reconstruction ability. | 2012-12-13 |
20120315320 | USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS - Disclosed are methods of increasing the chemosensitivity of normal and/or chemoresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof. Also disclosed are methods of increasing radiosensitivity of normal and/or radioresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof. | 2012-12-13 |
20120315321 | IMMUNOLOGICAL METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The present invention relates to immunogenic compositions and peptides comprising residues 4-10 (FRHDSGY) of the amyloid peptide Abeta | 2012-12-13 |
20120315322 | NANOPARTICLE MEDIATED GENE THERAPY AND THERAPEUTIC PRODUCTS FOR ALZHEIMERS - The present disclosure provides compositions and methods of treating Alzheimers Disease. In an aspect, a nanoparticle is paired to one or more genetic materials that regulates inflammation in a microenvironment. Such nanoparticles can be used to target predefined target cell types in connection with treatment of at least one of the following Alzheimer's disease, Pick's disease, Lewy Body disease, or Idiopathic dementia. | 2012-12-13 |
20120315323 | INFLUENZA HEMAGGLUTININ ANTIBODIES, COMPOSITIONS AND RELATED METHODS - Antibodies against influenza hemagglutinin, compositions containing the antibodies, and methods of using the antibodies are provided herein. | 2012-12-13 |
20120315324 | EXOSOMAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE - An exosomal composition is provided that comprises a therapeutic agent encapsulated by an exosome. The therapeutic agent can be a phytochemical agent, a chemotherapeutic agent, or a Stat3 inhibitor. Pharmaceutical compositions comprising the exosomal compositions are also provided. Methods for treating an inflammatory disease or a cancer are further provided and include administering an effective amount of an exosomal composition to a subject in need thereof to thereby treat the inflammatory disorder or the cancer. | 2012-12-13 |
20120315325 | PEPTIDE PHARMACEUTICAL FOR ORAL DELIVERY - Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds. | 2012-12-13 |
20120315326 | MULTIPARTICULATE L-CARNITINE COMPOSITIONS AND RELATED METHODS - Enteric coated multiparticulate compositions that use a L-carnitine compound an active ingredient are disclosed. The multiparticulates have spheroidal core comprising a L-carnitine, microcrystalline cellulose, and hydroxypropyl methylcellulose; a sub-coat comprising hydroxypropyl methyl cellulose on the spheroidal core; and an enteric coat on the sub-coated spheroidal core. The average diameter of the particulates is about 0.1-3 mm. Other aspects of the invention include methods of making and methods of using the multiparticulate compositions. | 2012-12-13 |
20120315327 | ANTI-DIABETIC COMPOSITION CONTAINING A PLANT EXTRACT OF ENGLERINA LECARDII - The invention relates to a pharmaceutical antidiabetic composition containing, among the active ingredients thereof, a plant extract of | 2012-12-13 |
20120315328 | CAPSULE OF COMPOUND DANSHEN DRIPPING PILLS - A capsule of compound danshen dripping pills are disclosed. The color of the capsule's shell is orange, yellow, green or blue and all of these colors are in the wavelength range of 446-620 nm. | 2012-12-13 |
20120315329 | SILOXANE SURFACE-MODIFIED HYDROGEL AND HYDROGEL MICROPARTICLE COMPOSITIONS - Embodiments of the present invention relate generally to siloxane surface-modified hydrogel microparticles and pastes, methods for their preparation, and uses thereof for delivery of personal care and healthcare active ingredients, as well as agricultural active ingredients. | 2012-12-13 |
20120315330 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ACUTE DISORDERS - A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders. | 2012-12-13 |
20120315331 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ACUTE DISORDERS - A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders. | 2012-12-13 |
20120315332 | PHARMACEUTICAL COMPOSITION INCLUDING SUNFLOWER EXTRACT, PREPARATIVE METHOD AND USE THEREOF - A pharmaceutical composition containing sunflower extract comprises the extract of total flavonoids from leaves, heads or stems of sunflower ( | 2012-12-13 |
20120315333 | DIRECT INKJET FABRICATION OF DRUG DELIVERY DEVICES - In some aspects of the present application, a method of forming one or more layers of at least a portion of a drug delivery device (DDD) is described. The method can include providing a substrate; providing one or more DDD components that are dissolved or dispersed in one or more pharmaceutically compatible phase change inks; ejecting, by one or more nozzles, a first portion of the one or more pharmaceutically compatible phase change inks to form a first layer on the substrate; and ejecting, by the one or more nozzles, a second portion of the pharmaceutically compatible phase change inks to form a second layer over the first layer. | 2012-12-13 |
20120315334 | PHARMACEUTICAL OR NEUTRACEUTICAL FORMULATION - The invention relates to a pharmaceutical or nutraceutical formulation comprising a core, comprising an active pharmaceutical or nutraceutical ingredient, a penetration promoter and a bioavailability promoting agent, and a polymeric coating for the gastrointestinal targeted release of the active ingredient, characterized in that the bioavailability promoting agent is a pharmaceutically acceptable inhibitor of proteolytic enzymes, which increases the oral bioavailability of the active ingredient by a factor of at least five, compared to a corresponding formulation without the bioavailability promoting agent. | 2012-12-13 |
20120315335 | SELF-ASSEMBLING NANOPARTICLE DRUG DELIVERY SYSTEM - A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting or facilitating molecules anchored in the lipid bilayer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided. | 2012-12-13 |
20120315336 | INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS - Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise particulate olanzapine. | 2012-12-13 |
20120315337 | MULTIPARTICULATE 5-HTP COMPOSITIONS AND RELATED METHODS - Enteric coated multiparticulate compositions that use 5-HTP as an active ingredient are disclosed. The multiparticulates have a spheroidal core comprising 5-HTP, microcrystalline cellulose, and hydroxypropyl methylcellulose; a sub-coat comprising hydroxypropyl methylcellulose on the spheroidal core; and an enteric coat on the sub-coated spheroidal core. The average diameter of the particulates is about 0.1-3 mm. Other aspects of the invention include methods of making and methods of using the multiparticulate compositions. | 2012-12-13 |
20120315338 | LARGE SCALE GENERATION OF FUNCTIONAL MEGAKARYOCYTES AND PLATELETS FROM HUMAN EMBRYONIC STEM CELLS UNDER STROMAL-FREE CONDITIONS - The present invention provides a method of generating megakaryocytes and platelets. In various embodiments, method involves the use of human embryonic stem cell derived hemangioblasts for differentiation into megakaryocytes and platelets under serum and stromal-free condition. In this system, hESCs are directed towards megakaryocytes through embryoid body formation and hemangioblast differentiation. Further provided is a method of treating a subject in need of platelet transfusion. | 2012-12-13 |
20120315339 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE - The present invention relates to a method for reducing the production of methane emanating from the digestive activities of a ruminant and or for improving ruminant animal performance by using, as active compound at least one nitrooxy alkanoic acid and/or derivative thereof, which is administrated to the animal together with the feed. The invention also relates to the use of these compounds in feed and feed additives such as premix, concentrates and total mixed ration (TMR) or in the form of a bolus. | 2012-12-13 |
20120315340 | Post-Charging Of Zeolite Doped Plastics With Antimicrobial Metal Ions - Methods of post-loading ceramic particles with antimicrobial metal cations are disclosed. In certain embodiments, the post-loaded particles are zeolites, wherein the zeolites have been incorporated into a resin and the combination is used as an implantable device. In certain embodiments, the polymer is a thermoplastic polymer such as polyaryletheretherketone (PEEK). In certain embodiments, the source of antimicrobial activity includes ion-exchangeable cations contained in a zeolite. In certain embodiments, disclosed are methods of imparting antimicrobial activity to devices by controlling the delivery of certain cations through ion-exchange via a zeolite incorporated in the device. | 2012-12-13 |
20120315341 | METHOD FOR TREATING AN INFLAMMATION OR LESION CAUSED BY A VIRUS - A method for treating an inflammation or lesion caused by herpes virus, comprising topically applying to said inflammation or lesion a composition comprising or consisting essentially of a C | 2012-12-13 |
20120315342 | EPITHELIAL CELL-CELL ADHESION ENHANCER, AND AMELIORATING, THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DISEASES USING SAME - Disclosed is a composition containing a specific oligosaccharide and a bivalent metal cation, which exhibits an effect on the amelioration, treatment or prevention of allergy or topical inflammatory reactions in an extremely safe and effective manner compared to synthetic oral steroid medicines in spite of a fact that the composition contains components that are generally familiar as a food or an ion occurring in living bodies and have no toxicity against living bodies when used at physiological concentrations. Specifically disclosed is a cell-cell adhesion enhancer in epithelial cells, which comprises 1-kestose and/or nystose and a bivalent metal cation as active ingredients. The enhancer can prevent the disruption of an epithelial cell-cell tight junction protein that causes the invasion of an allergen into the body, can repair the epithelial cell-cell tight junction protein or promote the formation of the epithelial cell-cell tight junction protein, whereby the epithelial cell-cell adhesion can be enhanced and the effective amelioration, treatment and prevention of allergic symptoms can be achieved. | 2012-12-13 |
20120315343 | SYNCHRONIZED WATER AND PRODUCTION AND USE THEREOF - A synchronized water is disclosed, in which all single water molecules at the same time are arranged in an identical way to a stable homogeneous microstructure, wherein said synchronized water in a distilled condition and at atmospheric pressure has a) a density of from 0.997855 to 0.998836 g/ml at 22° C., b) a water temperature at the freezing point of from −6.7° C. to −8.2° C., c) a melting point of from 0.1° C. to 0.2° C., d) a surface tension of from 72.3 to 72.7 dyn/cm at 22 and e) a dielectric constant of from 82.4 to 82.6 F/m, as well as a method for preparation thereof and different uses thereof. | 2012-12-13 |
20120315344 | Cosmetic Compositions and Methods for Using Same to Improve the Aesthetic Appearance of Skin - The present invention relates to compositions useful in treating the various signs of dermatological aging in human skin. The present invention also relates to cosmetic compositions and methods of using such compositions that improve the aesthetic appearance of skin. Further, the present invention relates to methods of applying the compositions to the skin to effect treatment and to improve the aesthetic appearance of skin, particularly, by providing anti-aging benefits to the skin. Suitable anti-aging agents include 3,3′-thiodipropionic acid and/or its derivatives. | 2012-12-13 |
20120315345 | FUNCTIONAL FOOD AND PHARMACEUTICAL COMPOSITIONS FOR ANTI-OBESITY COMPRISING CAPSANTHIN AND FATTY-ACYL ESTER OF CAPSANTHIN HAVING ANTI-ADIPOGENIC ACTIVITY - One or more embodiments of the present invention describe a novel use of capsanthin and/or fatty-acyl ester of capsanthin to inhibit both the differentiation of pre-adipocytes to adipocytes and the accumulation of fat in the adipocytes. One or more embodiments of the present invention are based on findings that capsanthin contained in some natural products such as red pepper, paprika, bell pepper, etc. have anti-adipogenic activity by inhibiting both the differentiation of pre-adipocyte into adipocyte and the accumulation of fat in adipocytes, Therefore, this findings provide a functional food and a pharmaceutical composition wherein capsanthins and the extract of any natural products containing the same components are included in the functional food and the pharmaceutical composition, to offer obesity prevention and/or treatment effects. | 2012-12-13 |
20120315346 | TIRE VULCANIZING DEVICE - A tire vulcanizing device includes a plurality of opening/closing cylinders for respectively independently moving a plurality of mold holding members, which respectively hold a plurality of segmented molds arranged in a circumference direction, forward and backward in radial directions, a plurality of positioning blocks arranged in respective spaces in the circumferential direction between the plurality of segmented molds, respective pairs of engaging members respectively provided at opposite sides of the respective mold holding members, and respective pairs of stopper members each pair of which are provided on the adjoining positioning blocks, for restricting the advanced end positions of the segmented molds in engagements with the respective pairs of engaging members. | 2012-12-13 |
20120315347 | System And Method For Manufacturing Fatty Acid Based Material Products With An Injection Molding Process - A system manufactures molded fatty acid based material products by forming a fatty acid based material paste and injecting the paste into a mold having internal cavities. The system includes a controller that regulates heat generated by a movable member in the barrel of an injection molding machine and a cooling jacket on the exterior of the barrel to enable nearly melted fatty acid material and nearly solid melted fatty acid material to mix within the barrel to form a paste that is ejected into a mold to form the products. The paste enables the products to form a skin that is less susceptible to shrinkage during cooling so the product is formed without voids that cause breakage or mar aesthetic appearances of the product. | 2012-12-13 |
20120315348 | COMPENSATION FOR HYDRAPAK MACHINE USING ISOLATOR CYLINDER - An apparatus and method for simultaneously forming and filling a plastic container is provided. A mold having a mold cavity defines an internal surface and is adapted to accept a preform. A pressure source is operable to draw liquid through the inlet and urge it into the preform. A blow nozzle may be adapted to receive the liquid from the pressure source and transfer the liquid at high pressure into the preform thereby urging the preform to expand toward the internal surface of the mold cavity and create a resultant container. A pressure compensation system can exert a clamping force on the mold in response to the pressure source. The liquid remains within the container as an end product. | 2012-12-13 |
20120315349 | TEMPLATE, TEMPLATE MANUFACTURING METHOD, AND TEMPLATE MANUFACTURING APPARATUS - According to one embodiment, a template includes: a base substrate; and a pattern portion provided on the base substrate and including a concave-convex pattern formed from a master pattern. The concave-convex pattern is provided in a distorted state with respect to the master pattern in accordance with a distortion of an underlying pattern formed on a substrate to which a shape of the concave-convex pattern is to be transferred. | 2012-12-13 |
20120315350 | CSD COOLING AND PRESSURIZATION TO KEEP CO2 IN SOLUTION DURING FORMING - A system for simultaneously forming and filling a container comprising a mold having a mold cavity defining an internal surface and adapted to accept a preform, a pressure source urging a first liquid toward the preform, means for maintaining a desired saturation of gas in solution in the first liquid, and a blow nozzle adapted to receive the first liquid from the pressure source and transfer the first liquid at a pressure into the preform thereby urging the preform to expand toward the internal surface of the mold cavity and create a resultant container, wherein the first liquid remains within the container as an end product. | 2012-12-13 |
20120315351 | WELDLESS-TYPE INJECTION MOLD APPARATUS - A weldless-type injection mold apparatus is provided. The weldless-type injection mold apparatus includes an upper mold, a lower mold engaged to the upper mold to form a cavity for injection-molding of products, a heating unit formed on one side of the cavity of at least one of the lower and upper molds to heat a resin injected into the cavity, a first cooling unit formed at the at least one of the lower and upper molds to prevent the injection mold from being over-heated, and a second cooling unit installed between the heating unit to cool an area surrounding the cavity and an injection-molded product. | 2012-12-13 |
20120315352 | High Calorie Food Product and Method - A food product high in calories from fat and carbohydrate is provided. The fat is incorporated in powder for later mixing with an aqueous medium to form a viscous liquid that is stable against phase separation of the oil and water. The product also includes protein and preferably at least one of vitamins and minerals. The food product has a low water activity and is packaged in a sealed container. | 2012-12-13 |
20120315353 | Breast Milk Collection, Storage, and Feeding System, Method, and Apparatus - Breast milk collection, storage, and feeding apparatus comprising a first storage bottle and first and second differently sized feeding bottles, each of the three bottles having a mouth portion of the same diameter and a common external thread structure, and first and second dual port caps each sized and threaded to attach to each of the three bottles, each dual port cap further having a drip port and a draw port, a pressure relief vent formed therein; and a tethered closure plug unit attached thereto, each tethered closure plug unit having first and second tethered plugs shaped and dimensioned to plug or close a respective one of the drip and draw ports. The apparatus may be used in various manners to transfer milk from the storage bottle to a feeding bottle and to thereafter feed an infant by nipple, syringe, or a gravity/bolus technique. | 2012-12-13 |
20120315354 | NATURAL TASTE ENHANCING SAVOURY BASE AND A PROCESS FOR ITS PREPARATION - The present invention concerns a taste enhancing savoury base comprising:—between 8 to 80% of naturally derived compounds taken in the group consisting of glutamate, IMP and GMP,—naturally food derived compounds such as organic acids and their salts, amino acids, peptides and aroma compounds, wherein said base is obtained through a prokaryotic fermentation with a bacteria taken from the group consisting of | 2012-12-13 |